ArticleNeoplasia (New York, N.Y.)2026
Spatial transcriptomics reveals atorvastatin modulates the tumor microenvironment to suppress breast cancer liver metastatic outgrowth.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metastatic breast cancer remains incurable, underscoring the need for novel therapeutic strategies. Epidemiological and preclinical evidence suggests statins suppress metastatic outgrowth, however the underlying mechanisms remain unclear. We employed high-resolution spatial transcriptomics (ST) to explore the cellular composition and differentially expressed genes (DEGs) in the metastatic microenvironment following atorvastatin treatment. Formalin-fixed, paraffin-embedded breast cancer liver metastases from control and atorvastatin-treated mice were analyzed by Nanostring CosMx Spatial Molecular Imager (SMI)/Bruker using a 973-gene panel, profiling 212 and 207 tumor-adjacent field of views (FOVs) (TAFs) respectively, which identified eight cell clusters, while non-tumor FOVs (NTFs) were sparse. Preferential depletion of LRRC15⁺ myofibroblastic cancer associated fibroblasts (CAFs), CXCL8⁺ inflammatory CAFs, and C1QC⁺/SPP1⁺ tumor associated macrophages (TAMs) subsets were revealed by harmony-assisted cell annotation and Seurat label transfer, which further separated CAFs and TAMs into discrete functional subpopulations. Immunohistochemistry (IHC) was also performed to validate cell types in both the tissues. Wilcoxon-based DEG analysis identified metastasis-associated gene expression changes between groups. Atorvastatin treatment reduced CAFs, Hepatic stellate cells (HSCs) (significantly), and macrophages (trending) in TAFs, with no changes in NTFs. These findings were supported by IHC (n = 4), which confirmed prominent reductions in these cell types while hepatocyte and endothelial markers remained unchanged. DEG analysis revealed coordinated downregulation of metastasis and extracellular matrix- associated transcripts in atorvastatin-treated TAFs. Our findings suggest that atorvastatin alters the cellular milieu in the disseminated microenvironment towards one in which pro-tumorigenic CAF and HSC populations are reduced, to create a microenvironmental niche favorable for maintaining metastatic dormancy and preventing relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.